Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 4 1

Status

Completed 28Recruiting 18Unknown 14Terminated 5Withdrawn 4Not yet recruiting 3Active not recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Prolymphocytic, T-Cell 1

Interventions

venetoclax 38Azacitidine 24fludarabine 20Cytarabine 18Cyclophosphamide 16Specimen Handling 14blinatumomab 13Biopsy 12Busulfan 8Dexamethasone 7Melphalan 6Daunorubicin 6Whole-Body Irradiation 5Vincristine 5Thiotepa 5Methotrexate 5Decitabine 5gilteritinib 4daratumumab 4Tacrolimus 4Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4Imatinib Mesylate 4Idarubicin 4Exercise 4Blood Specimen Collection 4zanubrutinib 3selinexor 3ruxolitinib 3revumenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Cladribine × Other hematologic neoplasm × Clear all
NCT07053020 2026-03-04

A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
58 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

NCT06763666 2025-01-08

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Nanfang Hospital, Southern Medical University

Phase 4 Not yet recruiting
172 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡